Posted by Michael Wonder on 15 May 2018
ICER posts draft scoping document on biologic treatments for asthma
15 May 2018 - Document open to public comment until 5 June 2018.
The ICER has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of biologic treatments for asthma. The scoping document will be open to public comment until 5pm ET on 5 June 2018.
ICER's report is expected to include five therapies: dupilumab (Dupixent, Sanofi/Regeneron), omalizumab (Xolair, Genentech/Novartis), mepolizumab (Nucala®, GlaxoSmithKline), reslizumab (Cinqair, Teva), and benralizumab (Fasenra, AstraZeneca). ICER previously reviewed mepolizumab for its use in severe eosinophilic asthma and dupilumab for its use in atopic dermatitis. Dupilumab is currently under FDA review for use as add-on maintenance treatment in moderate-to-severe asthma, with an approval decision expected in October of 2018.
